Status:
COMPLETED
Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
Lead Sponsor:
Prana Biotechnology Limited
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
56+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with ...
Eligibility Criteria
Inclusion
- diagnosis of probable early Alzheimer's disease
- stable dose of acetylcholinesterase inhibitor
- community dwelling
- stable medical condition
Exclusion
- unstable and significant medical conditions
- recurrent major psychiatric disorder
- treatment with memantine
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00471211
Start Date
December 1 2006
End Date
December 1 2007
Last Update
January 16 2008
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Sydney, New South Wales, Australia, 2031
2
Sydney, New South Wales, Australia, 2077
3
Adelaide, South Australia, Australia, 5011
4
Melbourne, Victoria, Australia, 3081